Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a price target of $285.
September 24, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen and maintained a price target of $285, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $285 price target by Needham suggests a positive outlook for Biogen, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100